Guanfacine in Children with Tourette’s Disorder or Chronic Tic Disorders
Principal Investigator: Barbara Coffey, MD, MS
Co-Investigators: Lawrence Scahill, MSN PhD; Tanya Murphy, MD
Sponsor: Shire Pharmaceuticals
Overview: This is a double blind pilot study designed to determine whether extended release guanfacine (an FDA-approved medication for high blood pressure and ADHD) is safe and beneficial in the treatment of children and adolescents with TD or Chronic Tic Disorder.
- Diagnosis of TD or chronic motor or vocal tic disorder
- Child must be unmedicated (or on stable medication treatment for OCD, anxiety, or depressive disorder for at least 8 weeks)
- Children on stable doses of an SSRI will be allowed to enter the trial
- Current primary diagnosis requiring pharmacotherapy
- Past or current history of abuse or diagnosis of Post-Traumatic Stress Disorder (PTSD)
- Significant medical condition that would be incompatible with the study drug, e.g., children with a history of cardiac arrhythmia
- Prior history of hypersensitivity to guanfacine or prior failed treatment with an adequate trial of guanfacine in the last 2 years
- Use of another psychotropic or a stimulant medication for tics
- Participation in behavioral therapy for tics
- Current participation in another research project involving medication therapy
Based on this information, if you think that you or your child might be a good candidate for this study and would like to be contacted by the study team to find out more, please complete this form.